Chinese Sinopharm says its coronavirus vaccine is 79% effective

An interim analysis of the phase 3 clinical trial showed that the vaccine is safe and that people who received the two doses produced high-level antibodies, according to a statement published Wednesday by Beijing Biological Products Institute Co. , A subsidiary of Sinopharm.

The company said it is seeking formal approval from Chinese regulators to distribute the vaccine to the public.

Coronavirus vaccines developed by Sinopharm have already been administered Hundreds of thousands of people Under the controversial emergency use program approved by the Chinese government.

By November, nearly a million people had received the Sinopharm vaccine, according to the company’s president, although he did not specify which vaccines they had received from the company.

Although few details were provided, the statement released on Wednesday said the vaccine meets the standards of the World Health Organization and the Chinese regulatory authority, the National Medical Products Administration.

Sinopharm vaccine is less effective than the one I developed Pfizer – Bioetec And the modernThat has an effectiveness of about 95%. Russia Satellite vaccine V It is 91% effective.
The vaccine efficacy rate is less than 79% 86% The United Arab Emirates announced the same vaccine on December 9th. The UAE based its findings on an interim analysis of late-stage clinical trials that were conducted there from July. It has since approved the vaccine for general use.
Sinopharm vaccine has a higher potency rate than the one developed by the UK University of Oxford and AstraZeneca, Which averaged 70%. On Wednesday, it became the United Kingdom The first country to approve this vaccine For general distribution.

A step closer to mass subtraction

Sinopharm results were announced weeks after its global competitors. With no details, it remains unclear whether the information provided will be sufficient to dispel doubts about the quality of the Chinese vaccines.

READ  Caribbean volcanoes come to life as scientists study activity not seen in years Volcanoes

However, the announcement could pave the way for the vaccine to be launched on a large scale within China and the world.

The country aims to vaccinate 50 million people with domestic Covid-19 vaccines ahead of Lunar New Year celebrations in February, a Chinese vaccination expert. Has been confirmed To CNN earlier this month.

China is ready to send hundreds of millions of doses to countries that have conducted last-phase trials of leading candidate vaccines. Chinese leaders have also promised a growing list of priority access developing countries.

Analysts say Beijing is using the global campaign as a tool of soft power to try to repair any damage to its image from its early mishandling of the coronavirus pandemic.

In China, there are five coronavirus candidates from four companies that have reached stage 3 clinical trials, which is the last and most important step in testing before seeking regulatory approval. After the spread of the Coronavirus within their borders has been largely eliminated, Chinese pharmaceutical companies have had to search abroad for places to test the effectiveness of their vaccines. Together, they launched Phase 3 trials in at least 16 countries.

Two of Sinopharm’s candidate vaccines are undergoing phase 3 trials in 10 countries, mostly in the Middle East and South America.

Chairman of the Sinopharm Liu Jing Chen He said Last month, dozens of countries ordered the company’s vaccines. He did not name the countries or say how much doses they suggested, but he said CNBG is capable of producing more than 1 billion doses in 2021.

Compared to Pfizer and Moderna, Sinopharm vaccines do not require freezing temperatures for storage, which makes transportation and distribution much easier – especially in developing countries that lack cold storage capabilities.

READ  Indonesia earthquake: At least 34 people are killed and hundreds injured in a powerful earthquake in Sulawesi

CNN’s Beijing office contributed to the reports.

Bir cevap yazın

E-posta hesabınız yayımlanmayacak. Gerekli alanlar * ile işaretlenmişlerdir